Use of Darbepoetin Alfa for the Treatment of Chemotherapy-induced Anaemia in European Clinical Practice - Data From the CHOICE Study

被引：0
|
作者：
Van Belle, S. [1 ]
Galid, A. [2 ]
Karanikiotis, C. [3 ]
Wheeler, T. [4 ]
Pujol, B. [5 ]
Labourey, J. L. [6 ]
机构：
[1] Ghent Univ Hosp, B-9000 Ghent, Belgium
[2] Hanusch KH, Gynecol & Obstet, Vienna, Austria
[3] Euromed Kyanous Stavros Hosp, Theassaloniki, Greece
[4] Amgen Ltd, Int Dev, Uxbridge, Middx, England
[5] Amgen Europe, Int Dev, Zug, Switzerland
[6] Ctr Hosp Antoine Gayraud, Carcassonne, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71217-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [31] Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy -- data from the CHOICE study
    Van Belle, S.
    Karanikiotis, C.
    Labourey, J. -L.
    Galid, A.
    Wheeler, T.
    Pujol, B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 987 - 994
  • [32] Clinical benefits and risks associated with darbepoetin alfa and epoetin alfa treatment in patients with lung cancer and chemotherapy-induced anemia.
    Tiotiu, Angelica
    Clerc-Urmes, Isabelle
    Chabot, Francois
    Martinet, Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Final results of a prospective, observational study of the effectiveness of darbepoetin alfa administered every three weeks for the treatment of chemotherapy-induced anaemia in elderly patients
    Esquerdo, G.
    Domenech, M.
    Bermejo, J. C.
    Lopez, P.
    Pedro, C.
    Villadiego, K.
    Constenla, M.
    Sanchez-Rovira, P.
    Gasquet, J. A.
    Rodriguez, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Epoetin Alfa and Darbepoetin Alfa in Clinical Practice in Patients With Chemotherapy Induced Anemia in the Netherlands (EVALUATE)
    van Groeningen, C. J.
    Kok, T. C.
    Biesma, B.
    Melissant, C. F.
    de Klerk, G.
    Brok, R. G. P. M.
    Lahaye, M.
    Milek, R. L. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S237 - S237
  • [35] Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia
    Boccia, Ralph
    Malik, Imtiaz A.
    Raja, Vinay
    Kahanic, Stephen
    Liu, Randall
    Lillie, Tom
    Tomita, Dianne
    Clowney, Billy
    Silberstein, Peter
    ONCOLOGIST, 2006, 11 (04): : 409 - 417
  • [36] Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
    Carrera, Fernando
    Burnier, Michel
    CLINICAL KIDNEY JOURNAL, 2009, 2 : I9 - I17
  • [37] Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia - Evidence from a 16-week randomised trial
    Reed, Shelby D.
    Radeva, Jasmina I.
    Daniel, Davey B.
    Mody, Samir H.
    Forlenza, Jamie B.
    McKenzie, R. Scott
    Schulman, Kevin A.
    PHARMACOECONOMICS, 2006, 24 (05) : 479 - 494
  • [38] Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in Non-Hodgkin's Lymphoma
    Gregory, SA
    Blayney, DW
    Vadhan-Raj, S
    Tomita, DK
    Rossi, G
    Mirtsching, B
    BLOOD, 2004, 104 (11) : 900A - 901A
  • [39] Clinical trial simulation of a 200-μg fixed dose of darbepoetin alfa in chemotherapy-induced anemia
    Jumbe, N
    Yao, B
    Rovetti, R
    Rossi, G
    Heatherington, AC
    ONCOLOGY-NEW YORK, 2002, 16 (10): : 37 - 44
  • [40] Darbepoetin alfa effectiveness in breast cancer patients Data from the CHOICE study
    Van Belle, S.
    Karanikiotis, C.
    Labourey, J. L.
    Galid, A.
    Wheeler, T.
    Pujol, B.
    BREAST, 2011, 20 : S81 - S81
12345